Share this with FacebookShare this with TwitterShare this with LinkedInEmail this pagePrint this page
Saint Luke’s Koontz Center for Advanced Breast Cancer Announces New Clinical Trial for Metastatic Triple Negative Breast Cancer
Metastatic triple negative breast cancer remains the most challenging subtype of breast cancer to treat. The Saint Luke’s Koontz Center for Advanced Breast Cancer will be one of five sites in the United States participating in novel clinical trial designed to test the effectiveness of a new combination of cancer drugs designed to treat triple negative breast cancer (TNBC).
Find out what this means for metastatic breast cancer patients by reading the full story here.